Overview

Lurasidone Pediatric Pharmacokinetics Study

Status:
Completed

Trial end date:
2013-05-01

Target enrollment:

Participant gender:

Summary

This is a Phase 1, open-label, multicenter, single and multiple ascending lurasidone dose study in subjects from 6 to 17 years old with schizophrenia spectrum, bipolar spectrum, autistic spectrum disorder, or other psychiatric disorders.

Phase:

Phase 1

Details

Lead Sponsor:

Sunovion

Treatments:

Lurasidone Hydrochloride